Trial Profile
Phase II Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Following Previous Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Penile cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Feb 2020 Status changed from recruiting to discontinued.
- 28 Dec 2016 Planned primary completion date changed from 1 Jul 2019 to 1 Oct 2019.
- 28 Dec 2016 Status changed from not yet recruiting to recruiting.